Alloimmunisation against paternal human platelet antigen (HPA) can result in fetomaternal alloimmune thrombocytopenia (FMAIT) and intracranial haemorrhage (ICH) in the fetus, both in the antenatal and perinatal period. Analysis of 200 confirmed cases of FMAIT, showed that HPA-1a antibodies accounted for 75% of all cases and ICHs, with long-term neurological disabilities in 72%. Clinical data showed that antenatal treatment of alloimmunised pregnancies with intrauterine transfusions (lUT) carried a 15% risk of intrauterine death (lUD) and that postnatal treatment with HPA-1a negative platelet was effective but not used consistently.
| Identifer | oai:union.ndltd.org:bl.uk/oai:ethos.bl.uk:489916 |
| Date | January 2008 |
| Creators | Ghevaert, Cedric |
| Publisher | Open University |
| Source Sets | Ethos UK |
| Detected Language | English |
| Type | Electronic Thesis or Dissertation |
Page generated in 0.002 seconds